Test Price
2,800 AED✅ Home Collection Available
COCH Gene Deafness, Autosomal Dominant Type 9 Genetic Test in UAE | 2800 AED | DHA Licensed
Executive Summary & Core Metrics
- ✓ Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO‑certified processing.
- ✓ Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily 8 AM to 11 PM).
- ✓ Clinical Guidance: Telephonic Post‑Test Clinical Interpretation provided by a DHA‑licensed specialist.
- ✓ Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731
This advanced genetic test provides high diagnostic accuracy for COCH gene mutations associated with hereditary dominant deafness, using next‑generation sequencing with full exon coverage.
Test Overview & Methodology
This advanced genetic test screens the entire coding region of the COCH gene using Next Generation Sequencing (NGS) to detect pathogenic variants linked to autosomal dominant non‑syndromic hearing loss type 9 (DFNA9). The test covers all exons and splice‑site junctions, providing comprehensive diagnostic coverage.
| Feature | Our Test (NGS‑DFNA9) | Closest Alternative (Sanger COCH) |
|---|---|---|
| Methodology | NGS (Next Generation Sequencing) – full gene coverage | Sanger sequencing of selected exons |
| Diagnostic Sensitivity | 99.9% for known pathogenic variants | ~95% (limited to screened regions) |
| Turnaround Time | 3–4 Weeks | 2–3 Weeks |
| Price | 2800 AED | ~2000 AED |
| Complete Exon & Splice‑Site Analysis | ✔ Yes | No (only selected hotspots) |
Physician Insight & Safety Protocols
Safety Advisories
Medication Warning: Do not discontinue prescribed medication without consulting your doctor.
Exclusion Criteria & Emergency Red Flags
- Exclusion: Not intended for standalone prenatal diagnosis; must be accompanied by genetic counselling. Not recommended for asymptomatic minors without documented family history of DFNA9.
- ER Red Flags: Sudden total hearing loss in one or both ears, acute rotational vertigo with nystagmus, pulsatile tinnitus with neurological signs, or severe imbalance causing falls. Seek immediate emergency care.
- Pre‑Test Counselling: A genetic counselling session and clinical history documentation are mandatory prior to sample collection to ensure proper interpretation and family pedigree analysis.
- Sample Integrity: This test accepts whole blood (EDTA), extracted DNA, or a single drop of blood on an FTA card. Improper collection may lead to rejection; our phlebotomist follows strict ISO protocols.
Patient FAQ & Clinical Guidance
1. What is the COCH gene test and why is it done?
This NGS test identifies COCH gene mutations causing progressive sensorineural hearing loss and balance problems. It is primarily performed to confirm a clinical suspicion of DFNA9 in adults with post‑lingual, often mid‑frequency onset hearing loss and vestibular dysfunction. Early diagnosis helps tailor management, predict progression, and guide family planning.
2. How is the sample collected and what preparation is required?
A blood sample, extracted DNA, or a single drop of blood on an FTA card is collected by our certified phlebotomist. No fasting or special preparation is needed. However, a pre‑genetic counselling session and a detailed clinical history are highly recommended to ensure accurate interpretation of the result. Our team provides at‑home sample collection with complete cold‑chain logistics.
3. What does a positive result mean and what are the next steps?
A positive COCH gene variant confirms DFNA9 diagnosis, prompting referrals to ENT and genetic counseling. Management typically includes audiological rehabilitation (hearing aids, possible cochlear implants if eligible), vestibular therapy, and regular monitoring. Cascade testing of first‑degree relatives is strongly advised to identify at‑risk individuals before symptoms appear.
UAE Regulatory & Data Privacy Adherence
DHA Compliance: This test is performed under DHA Facility License number 1143, in full alignment with Dubai Healthcare City regulations.
Data Protection: All patient data is handled in strict accordance with Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields.
Clinical Safety: Patient consent and clinical safety follow Federal Decree‑Law No. 4 of 2016 on Medical Liability.
Clinical & Logistical Metadata
| Test Name | COCH Gene Deafness, Autosomal Dominant Type 9 (DFNA9) – NGS Full Gene Sequencing |
| Price (AED) | 2,800 |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Whole Blood (EDTA), Extracted DNA, or FTA Card Dried Blood Spot |
| Methodology Used | Next Generation Sequencing (NGS) – Full coding region and splice sites |
| ICD-10-CM Code | H90.3 (Sensorineural hearing loss, bilateral) |
| LOINC Code | 21636-6 (Gene mutation detection in blood) |
| DHA Facility License & Address | License No: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE – DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians